Aquestive Therapeutics Inc Total Liabilities
Aquestive Therapeutics Inc total liabilities. Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has total liabilities worth $175.18 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AQST cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aquestive Therapeutics Inc (2005–2025)
Total liabilities of Aquestive Therapeutics Inc from 2005 to 2025. This chart illustrates how Aquestive Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Aquestive Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Aquestive Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aquestive Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lake Materials Co. Ltd.
KQ:281740
|
Korea | ₩254.24 Billion |
|
Zhangjiagang Guangda Special Material Co Ltd
SHG:688186
|
China | CN¥7.41 Billion |
|
Changchun Gas Co Ltd
SHG:600333
|
China | CN¥5.16 Billion |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
China | CN¥187.91 Million |
|
Grupo Supervielle S.A
F:189A
|
Germany | €5.10 Trillion |
|
China Oil HBP Science & Technology Co Ltd
SHE:002554
|
China | CN¥3.61 Billion |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
China | CN¥1.94 Billion |
|
Northern United Publishing & Media Group Co Ltd
SHG:601999
|
China | CN¥1.41 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Aquestive Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Aquestive Therapeutics Inc.
Liquidity & Leverage Metrics
Aquestive Therapeutics Inc Total Liabilities Ratios Explained
Aquestive Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aquestive Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual total liabilities of Aquestive Therapeutics Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $194.09 Million | +20.12% |
| 2024-12-31 | $161.58 Million | -1.42% |
| 2023-12-31 | $163.91 Million | -6.67% |
| 2022-12-31 | $175.62 Million | +21.85% |
| 2021-12-31 | $144.13 Million | +29.40% |
| 2020-12-31 | $111.38 Million | +31.65% |
| 2019-12-31 | $84.60 Million | +10.20% |
| 2018-12-31 | $76.77 Million | +10.29% |
| 2017-12-31 | $69.61 Million | +22.20% |
| 2016-12-31 | $56.97 Million | +2873.12% |
| 2006-12-31 | $1.92 Million | -74.92% |
| 2005-12-31 | $7.64 Million | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more